Treating mild hypertension--an unnecessary luxury

Area of Science:

• Cardiology
• Clinical Pharmacology
• Evidence-Based Medicine

Background:

• Clinical practice for high blood pressure (hypertension) historically lacked definitive evidence.
• Individual physician opinions were often the basis for treatment decisions.
• The concept of an 'acceptable upper limit' for blood pressure required empirical data.

Purpose of the Study:

• To emphasize the critical role of large-scale clinical trials in guiding hypertension management.
• To advocate for evidence-based treatment decisions over subjective medical opinions.
• To highlight the need for assessing the benefit-risk profile of all hypertension medications.

Main Methods:

• Review of findings from major clinical trials, specifically mentioning the MRC trial.
• Analysis of treatment benefits in relation to the incidence of adverse effects.
• Comparison of established drugs with newer, less-tested pharmacological agents.

Main Results:

• Large clinical trials have successfully identified acceptable upper limits for blood pressure.
• Established treatments, like bendrofluazide and propranolol from the MRC trial, demonstrate assessable benefits and risks.
• Many newer, expensive hypertension drugs lack sufficient large-scale trial data for benefit-risk assessment.

Conclusions:

• Clinical decisions for hypertension must be grounded in rigorous clinical trial data.
• Newer hypertension drugs without extensive trial validation are considered unnecessary and undesirable luxuries.
• Evidence-based medicine, supported by large trials, is essential for safe and effective patient care.